A Patient Charter for Chronic Obstructive Pulmonary Disease.
Caregivers
Chronic obstructive pulmonary disease
Patient advocacy
Patient care
Quality of life
Socioeconomic factors
Treatment outcome
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
13
10
2020
accepted:
16
11
2020
pubmed:
28
11
2020
medline:
15
4
2021
entrez:
27
11
2020
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) has a profound impact on people living with the disease and has a high global economic and social burden. Often, people with COPD are undiagnosed, while those diagnosed are undertreated and undereducated on different aspects of COPD care. Although there are many published evidence-based treatment guidelines from different expert groups and societies, they are frequently not adhered to, which results in significant gaps in care. In particular, 'flare-ups' (known as exacerbations of COPD), which accelerate disease progression, are often under-reported, despite guidelines recommending an escalation of maintenance treatment to prevent subsequent flare-ups. Management of COPD should be proactive to prevent worsening of symptoms and to reduce the risk of future flare-ups and premature death, rather than a secondary reaction to a worsening health status. Key to this is patient access to accurate diagnosis, effective treatment and specialist care, which can vary widely due to socioeconomic differences, geographical locations and poor guideline implementation. In addition, the stigma associated with COPD can act as a barrier, which can result in people being reluctant to access treatment or clinicians being nihilistic. As global patient advocates, we have co-developed this patient charter to set a standard of care that people living with COPD should expect, raising awareness and understanding of the causes and consequences of COPD as well as the potential to improve patient care. Patients with COPD should be empowered to live the highest quality of life possible with the least number of flare-ups. We set out six principles in line with current COPD guideline recommendations, that should be implemented by governments, healthcare providers, policymakers, lung health industry partners and patients/caregivers to drive meaningful change in COPD care.
Identifiants
pubmed: 33245531
doi: 10.1007/s12325-020-01577-7
pii: 10.1007/s12325-020-01577-7
pmc: PMC7854443
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
11-23Références
Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111–22.
pubmed: 26154786
doi: 10.1056/NEJMoa1411532
pmcid: 26154786
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. 2020. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf . Accessed 11 Nov 2020.
Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:1130–9.
pubmed: 29979608
doi: 10.1164/rccm.201804-0621CI
pmcid: 29979608
Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chronic Obstruct Pulm Dis. 2014;9:889–904.
doi: 10.2147/COPD.S62750
Albitar HAH, Iyer VN. Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions. Curr Opin Pulm Med. 2020;26:149–54.
pubmed: 31834001
doi: 10.1097/MCP.0000000000000655
pmcid: 31834001
Worth H, Buhl R, Criee CP, Kardos P, Mailander C, Vogelmeier C. The ‘real-life’ COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71.
pubmed: 26775251
doi: 10.1016/j.rmed.2015.12.010
pmcid: 26775251
Tabyshova A. Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review. Chest. 2020. (Published Online 7 October).
Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415.
pubmed: 26755942
pmcid: 4693508
doi: 10.7189/jogh.05.020415
World Health Organization. The top 10 causes of death. 2018. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death . Accessed 22 July 2020.
British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics. 2012. https://statistics.blf.org.uk/copd . Accessed 11 Nov 2020.
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706.
doi: 10.1016/S2213-2600(17)30293-X
Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chronic Obstruct Pulm Dis. 2016;11:2625–32.
doi: 10.2147/COPD.S118523
Nishimura S, Zaher C. Cost impact of COPD in Japan: opportunities and challenges? Respirology. 2004;9:466–73.
pubmed: 15612957
doi: 10.1111/j.1440-1843.2004.00617.x
Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e56–69.
pubmed: 32283960
pmcid: 7193862
doi: 10.1164/rccm.202003-0625ST
Wedzicha JA, ERS Co-Chair, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791.
doi: 10.1183/13993003.00791-2016
Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3:210–32.
Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–37.
pubmed: 26797035
pmcid: 4733567
doi: 10.1183/13993003.01170-2015
Larsson K, Janson C, Ställberg B, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. Int J Chronic Obstruct Pulm Dis. 2019;14:995–1008.
doi: 10.2147/COPD.S195382
van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chronic Obstruct Pulm Dis. 2013;8:461–71.
doi: 10.2147/COPD.S49392
Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92.
pubmed: 21991892
doi: 10.1056/NEJMoa1105482
Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
pubmed: 19566934
pmcid: 2714501
doi: 10.1186/1465-9921-10-59
Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:324–30.
pubmed: 27556408
pmcid: 5328181
Gershon AS, Hwee J, Chapman KR, et al. Factors associated with undiagnosed and overdiagnosed COPD. Eur Respir J. 2016;48:561–4.
pubmed: 27338199
doi: 10.1183/13993003.00458-2016
Labonté LE, Tan WC, Li PZ, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD study. Am J Respir Crit Care Med. 2016;194:285–98.
pubmed: 26836958
doi: 10.1164/rccm.201509-1795OC
Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chronic Obstruct Pulm Dis. 2013;8:231–8.
doi: 10.2147/COPD.S42866
Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043–8.
pubmed: 19569976
doi: 10.1185/03007990903103006
Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.
pubmed: 24143997
pmcid: 3816156
doi: 10.1186/1465-9921-14-112
Agusti A, Hedner J, Marin JM, Barbé F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183–94.
pubmed: 21881146
doi: 10.1183/09059180.00004311
Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590–8.
pubmed: 24488571
doi: 10.1183/09031936.00196713
Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest. 2007;132:403–9.
pubmed: 17550936
doi: 10.1378/chest.06-2846
pmcid: 17550936
Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811–21.
pubmed: 27168432
pmcid: 4968204
doi: 10.1056/NEJMoa1505971
Mosenifar Z. Chronic obstructive pulmonary disease (COPD) treatment & management. 2019. https://emedicine.medscape.com/article/297664-treatment . Accessed 22 July 2020.
Westerik JAM, Metting EI, van Boven JFM, Tiersma W, Kocks JWH, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18:31.
pubmed: 28166777
pmcid: 5294875
doi: 10.1186/s12931-017-0512-2
Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. Respir Investig. 2015;53:249–58.
pubmed: 26521102
doi: 10.1016/j.resinv.2015.02.004
pmcid: 26521102
Zwerink M, Brusse-Keizer M, van der Valk PD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;CD002990.
Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948–55.
pubmed: 19729663
doi: 10.1164/rccm.200906-0876OC
pmcid: 19729663
Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. Am J Respir Crit Care Med. 2020;201:1508–16.
pubmed: 32162970
pmcid: 7301738
doi: 10.1164/rccm.201911-2207OC
Scuri M, Fabbri LM, Singh D, et al. Reduction in fatal events with ICS-containing medications: results of safety pooled analysis from the TRILOGY, TRINITY and TRIBUTE studies [abstract]. Am J Respir Crit Care Med. 2018;197:A7725.
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48.
pubmed: 32579807
doi: 10.1056/NEJMoa1916046
pmcid: 32579807
Johnston KN, Young M, Grimmer-Somers KA, Antic R, Frith PA. Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitioners. Int J Chronic Obstruct Pulm Dis. 2011;6:659–67.
doi: 10.2147/COPD.S26581
Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and medicare patients. Int J Chronic Obstruct Pulm Dis. 2012;7:1–9.
Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinMed. 2019;14:32–41.
Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respir Med. 2016;4:473–526.
pubmed: 27185520
doi: 10.1016/S2213-2600(16)00094-1
pmcid: 27185520
Xu W, Collet J-P, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J. 2010;35:1022–30.
pubmed: 19897555
doi: 10.1183/09031936.00079409
pmcid: 19897555
Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chronic Obstruct Pulm Dis. 2017;12:2891–908.
doi: 10.2147/COPD.S139470
Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:464–71.
pubmed: 29474094
pmcid: 6118021
doi: 10.1164/rccm.201710-2029OC
Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091–7.
pubmed: 20022970
doi: 10.1378/chest.09-2029
pmcid: 20022970
Kessler R, Ståhl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006;130:133–42.
pubmed: 16840393
doi: 10.1378/chest.130.1.133
pmcid: 16840393
Dalal AA, Shah MB, D’Souza AO, Lunacsek OE, Nagar SP, Crater GD. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Respir Res. 2012;13:41.
pubmed: 22651541
pmcid: 3490761
doi: 10.1186/1465-9921-13-41
Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD audit. Eur Respir J. 2016;47:113–21.
pubmed: 26493806
doi: 10.1183/13993003.01391-2014
Lane ND, Brewin K, Hartley TM, et al. Specialist emergency care and COPD outcomes. BMJ Open Respir Res. 2018;5:e000334.
pubmed: 30397485
pmcid: 6203006
doi: 10.1136/bmjresp-2018-000334
Royal College of Physicians. National Asthma and COPD Audit Programme (NACAP): COPD clinical audit 2017/18. 2019. https://www.rcplondon.ac.uk/projects/outputs/national-asthma-and-copd-audit-programme-nacap-copd-clinical-audit-201718 . Accessed 22 July 2020.
European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). Minimum standards of care for COPD patients in Europe. 2014. https://www.efanet.org/images/2014/10/EFA-Book-Minimum-Standards-of-Care-for-COPD-Patients-in-Europe_ENGLISH.pdf . Accessed 22 July 2020.
Croft JB, Lu H, Zhang X, Holt JB. Geographic accessibility of pulmonologists for adults with COPD: United States, 2013. Chest. 2016;150:544–53.
pubmed: 27221645
pmcid: 5304918
doi: 10.1016/j.chest.2016.05.014
Fromer L. Implementing chronic care for COPD: planned visits, care coordination, and patient empowerment for improved outcomes. Int J Chronic Obstruct Pulm Dis. 2011;6:605–14.
doi: 10.2147/COPD.S24692
Alwashmi M, Hawboldt J, Davis E, Marra C, Gamble JM, Abu AW. The effect of smartphone interventions on patients with chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysis. JMIR Mhealth Uhealth. 2016;4:e105.
pubmed: 27589898
pmcid: 5025564
doi: 10.2196/mhealth.5921
Russell S, Ogunbayo OJ, Newham JJ, et al. Qualitative systematic review of barriers and facilitators to self-management of chronic obstructive pulmonary disease: views of patients and healthcare professionals. NPJ Prim Care Respir Med. 2018;28:2.
pubmed: 29343739
pmcid: 5772437
doi: 10.1038/s41533-017-0069-z
Lippiett KA, Richardson A, Myall M, Cummings A, May CR. Patients and informal caregivers’ experiences of burden of treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a systematic review and synthesis of qualitative research. BMJ Open. 2019;9:e020515.
pubmed: 30813114
pmcid: 6377510
doi: 10.1136/bmjopen-2017-020515
Bergdahl IA, Torén K, Eriksson K, et al. Increased mortality in COPD among construction workers exposed to inorganic dust. Eur Respir J. 2004;23:402–6.
pubmed: 15065829
doi: 10.1183/09031936.04.00034304
Humerfelt S, Gulsvik A, Skjærven R, et al. Decline in FEV
pubmed: 8224123
Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD. 2011;8:400–7.
pubmed: 22149399
doi: 10.3109/15412555.2011.611200
Balcan B, Akan S, Ugurlu AO, Handemir BO, Ceyhan BB, Ozkaya S. Effects of biomass smoke on pulmonary functions: a case control study. Int J Chronic Obstruct Pulm Dis. 2016;11:1615–22.
doi: 10.2147/COPD.S109056
Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty–a BOLD analysis. Thorax. 2014;69:465–73.
pubmed: 24353008
doi: 10.1136/thoraxjnl-2013-204460
Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–9.
pubmed: 12365965
doi: 10.1001/jama.288.14.1775
Reynolds R, Dennis S, Hasan I, et al. A systematic review of chronic disease management interventions in primary care. BMC Fam Pract. 2018;19:11.
pubmed: 29316889
pmcid: 5759778
doi: 10.1186/s12875-017-0692-3
Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163:461–4.
pubmed: 26259067
doi: 10.7326/M15-0288